On March 1, 2022 ImmVira reported that its global first intravenous administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed first dosing on March 1, 2022 and initiated Phase I clinical trial in a series of well-known domestic clinical study centers in China (Press release, Immvira, MAR 1, 2022, View Source [SID1234609304]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Preliminary data from MVR-T3011 IV U.S. Phase I clinical study has demonstrated robust safety results. We have full confidence in its clinical application. With the completion of first dosing in China, we will rapidly advance the clinical development progress for MVR-T3011 IV in both the U.S. and China simultaneously. Leveraging its proprietary OvPENS platform which supports the development of next-generation oncolytic virotherapy, ImmVira will continue to create groundbreaking cancer treatment paradigms that reignites hope for cancer patients around the world." ImmVira’s Chairwoman and CEO Dr. Grace Zhou said.

MVR-T3011 IV is ImmVira’s proprietary 3-in-1 oHSV with novel virus backbone modification strategy, allowing the great breakthrough in intravenous administration. Intravenous injection ("IV") is an important approach for oncolytic virus to treat metastatic tumors. By overcoming the clinical application limitations of local injection, intravenous injection can provide a consistent local and systemic oncolytic virotherapy for patients and increase the flexibility of oncolytic virus in combination with other drugs. Leveraging the OvPENS new drug R&D platform, ImmVira, as a leader in oncolytic virus development industry, will continue to expand its pipelines, actively explore monotherapy and combination therapies of MVR-T3011 IV and broaden the administration methods of oncolytic virus, providing new treatment opportunities for patients with late-stage cancers.

On March 1, 2022 Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates" or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, reported that it will participate in several upcoming investor conferences (Press release, Molecular Templates, MAR 1, 2022, View Source [SID1234609303]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details can be found below:

Cowen’s 42nd Annual Health Care Conference (March 7-9, 2022)
Format:
Corporate Presentation
Date: Tuesday, March 8th
Time: 10:30 AM – 11:00 AM ET

Oppenheimer’s 32nd Annual Healthcare Conference (March 15-16, 2022)
Format:
Corporate Presentation
Date: Wednesday, March 16
Time: 2:00 PM – 2:30 PM ET

Barclays Global Healthcare Conference 2022 (March 15-17, 2022)
Format:
Corporate Presentation
Date: Tuesday, March 15
Time: 4:20 PM – 4:45 PM ET
Webcast links for the presentations will be posted on the "News and Media" section of the Molecular Templates corporate website, under Events.

On March 1, 2022 Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer’s 32nd Annual Healthcare Conference (Press release, Aptose Biosciences, MAR 1, 2022, View Source [SID1234609302]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aptose Presentation – Oppenheimer’s 32nd Annual Healthcare Conference
Date: Tuesday, March 15, 2022
Time: 10:00 – 10:30 ET
Format: Virtual
Webcast: Link
The audio webcast also will be accessible through the Aptose website at www.aptose.com and will be archived shortly after the live events.

On March 1, 2022 XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, reported its Chairman and Chief Executive Officer, Jim Neal, will be featured in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 1:30 PM ET (Press release, Xoma, MAR 1, 2022, View Source [SID1234609301]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation can be accessed at https://bit.ly/3rPGmLl or by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of the presentation will be available and archived on the site for 90 days after the event.

On March 1, 2022 iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, reported that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. ET (Press release, iTeos Therapeutics, MAR 1, 2022, https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-present-cowen-42nd-annual-health-care-conference [SID1234609300]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the virtual presentation will be available on the Investors section of the company’s website at View Source An archived replay will be available for approximately 30 days following the presentation.